Nisa Investment Advisors LLC Makes New $26,000 Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Nisa Investment Advisors LLC acquired a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,828 shares of the biotechnology company’s stock, valued at approximately $26,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in Aclaris Therapeutics by 3.4% in the 1st quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company’s stock worth $98,789,000 after buying an additional 190,985 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Aclaris Therapeutics by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 2,728,820 shares of the biotechnology company’s stock worth $47,045,000 after buying an additional 10,713 shares in the last quarter. RA Capital Management L.P. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $31,339,000. State Street Corp increased its position in shares of Aclaris Therapeutics by 3.4% in the 1st quarter. State Street Corp now owns 1,083,390 shares of the biotechnology company’s stock worth $18,678,000 after purchasing an additional 36,000 shares during the last quarter. Finally, Great Point Partners LLC increased its position in shares of Aclaris Therapeutics by 17.8% in the 1st quarter. Great Point Partners LLC now owns 942,445 shares of the biotechnology company’s stock worth $16,248,000 after purchasing an additional 142,445 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insiders Place Their Bets

In other Aclaris Therapeutics news, Director Andrew N. Schiff sold 14,616 shares of the company’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $17.01, for a total value of $248,618.16. Following the completion of the transaction, the director now owns 514,939 shares in the company, valued at approximately $8,759,112.39. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Joseph Monahan sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $15.98, for a total value of $79,900.00. Following the completion of the sale, the insider now directly owns 101,386 shares of the company’s stock, valued at approximately $1,620,148.28. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Andrew N. Schiff sold 14,616 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $17.01, for a total transaction of $248,618.16. Following the completion of the sale, the director now directly owns 514,939 shares of the company’s stock, valued at $8,759,112.39. The disclosure for this sale can be found here. In the last 90 days, insiders sold 99,639 shares of company stock worth $1,644,933. Insiders own 6.70% of the company’s stock.

Analyst Ratings Changes

ACRS has been the subject of several research analyst reports. SVB Leerink reissued an “outperform” rating on shares of Aclaris Therapeutics in a research report on Tuesday. StockNews.com initiated coverage on shares of Aclaris Therapeutics in a research report on Wednesday, October 12th. They issued a “sell” rating for the company. BTIG Research started coverage on shares of Aclaris Therapeutics in a research report on Thursday, October 6th. They issued a “buy” rating and a $32.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aclaris Therapeutics in a research report on Monday, August 1st. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $36.00.

Aclaris Therapeutics Stock Up 0.2 %

Shares of NASDAQ:ACRS opened at $16.99 on Friday. Aclaris Therapeutics, Inc. has a fifty-two week low of $9.26 and a fifty-two week high of $18.59. The firm has a 50-day simple moving average of $15.57 and a 200 day simple moving average of $14.98. The company has a market cap of $1.13 billion, a PE ratio of -13.17 and a beta of 0.55.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Further Reading

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.